Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION - Wikidata - wikimedia - TriplyDB

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

http://www.wikidata.org/entity/Q27653715

about

Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1 Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways The DAN family: modulators of TGF-β signaling and beyond High Resolution NMR-based Model for the Structure of a scFv-IL-1 Complex: POTENTIAL FOR NMR AS A KEY TOOL IN THERAPEUTIC ANTIBODY DESIGN AND DEVELOPMENT Mycobacterium tuberculosis RNA Polymerase-binding Protein A (RbpA) and Its Interactions with Sigma Factors Structure of Protein Related to Dan and Cerberus: Insights into the Mechanism of Bone Morphogenetic Protein Antagonism A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density WNT signaling in bone homeostasis and disease: from human mutations to treatments Regulation of Wnt/β-catenin signaling within and from osteocytes Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition Structure of Gremlin-1 and analysis of its interaction with BMP-2 Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists.Conformational heterogeneity in antibody-protein antigen recognition: implications for high affinity protein complex formation Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms.Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.Sclerostin: current knowledge and future perspectives.Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.Romosozumab for the treatment of osteoporosis.Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.Sclerostin and Dickkopf-1 in renal osteodystrophy.An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.Association of circulating sclerostin with vascular calcification in Afro-Caribbean men.Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097.Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis.Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.Heparanase Overexpression Reduces Hepcidin Expression, Affects Iron Homeostasis and Alters the Response to Inflammation.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6 TGF-β antagonists: same knot, but different hold.Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist.Predicting intrinsic disorder in proteins: an overview.Relative influence of heritability, environment and genetics on serum sclerostin Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

P2860

Q24300782-81EE99EC-EB8A-4447-9CB8-2D5256B7F20E Q24609669-6B997947-D377-4802-AAE7-08C1C17FE361 Q24621990-875C3305-63AB-4AA8-8E00-578590104B11 Q27025762-E94DB2EA-8197-46BB-868B-40DE86B43D3C Q27657542-FFA8C553-F19C-4B65-933B-43DF107CAFC9 Q27677177-2DD91402-687C-42E3-95F0-413F63C511CF Q27679073-BD1DF087-C969-4CDA-AD41-7F5837DD962F Q28247445-7044B997-6784-4664-A541-1E1AE17E0F6C Q28285090-B187FE33-4EBB-47D3-A004-31FF7F7E6550 Q28286814-0BF90C73-1273-4DB0-830A-4C10627796CD Q28535490-8F321803-0F76-44BC-982B-5A4FAD2574DC Q30090218-CDFB983D-0E9D-4DB5-9D73-36F9E4F25E4E Q30090227-F420D8C8-CCE9-40E8-B2A6-69FE892293D3 Q30357995-4522D96C-530E-4D6E-9EE0-40865F426336 Q33564617-AA283FF7-D1F3-4697-AC03-9F487296D6C0 Q33627749-88C72C3C-524A-41E0-9E70-658A37899543 Q33835723-F61F8881-9B00-4B8A-A356-0D6057E73C9A Q33992612-4EE2284E-1A4D-45ED-806F-9B3837AB7999 Q34537434-D500B834-ABEC-4CD0-BF70-510034CEB85E Q34680463-EADE10BE-4E83-4E3F-8694-E8DF5574CE74 Q34701183-FFBB1304-6343-4284-B0BE-1F473309F3F0 Q34751932-A04C7B11-A390-4C57-A974-68B57434F9CA Q35085009-9DA1B79C-22A1-4932-AE03-321D6AF5289C Q35091260-AA1182EB-E0DC-4802-A751-4B0B0B0699EE Q35101832-FDA2B328-26B8-4FE3-B6CF-F3838A0D9837 Q35596559-FBD5CC3C-1F42-480D-91A1-FC634452B161 Q35694436-05587C55-7E31-4AE0-B7D5-5A11E46EB8EC Q35755034-5811994E-B021-436C-A50D-38B0FDA58076 Q36104814-72E263D2-BE60-46E8-88F7-06B0ADC351AD Q36143916-F980C0C2-F62B-44E0-8CE0-D0CDC8ADC4B2 Q36155327-C9B5F7B2-6FAE-486D-95DA-FBA637C7A203 Q36256294-800AE43E-53A2-4C98-9B8B-966FF2DAB071 Q36762750-112C2D5F-D0AF-4B9C-9BF6-5DFC78BB4F04 Q36793394-663C59F0-C984-4214-8C76-4AA85B38069C Q37224687-AC6DEE61-E77E-4A52-93B2-1EA064AE4E4D Q37257108-7E04AB25-3EF7-441D-A906-F4B9DCB34E35 Q37376551-D2EC4784-7BC7-4AE8-B011-C901C3A2D666 Q37549950-7FB258B7-EF74-4E62-9F97-CB21E28C76CB Q37627846-6D6CF5A6-BC86-443D-9CCA-AE65F0657968 Q37640833-9664DFD6-D715-467E-8FCA-27B9A1AABB3F

P2860

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

http://www.wikidata.org/entity/Q27653715

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@ast

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@en

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@nl

type

label

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@ast

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@en

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@nl

prefLabel

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@ast

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@en

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@nl

P1433

Q27653715-B14A62F1-D83F-49CA-8B90-BC21BB0EBA9C

P1476

Q27653715-BCEFB2E9-B2B8-4CFF-A885-5A0DCFCC50F4

P2093

Q27653715-211160EF-9EDE-4216-8E6E-01D40D6F58B8

Q27653715-33D73CD4-69CA-4DB2-8761-E9AE5BDAE843

Q27653715-5E8A0A1D-176A-4CF2-A6C2-C39B015D82EB

Q27653715-65419874-A4DB-4F94-8893-4FFE51A06096

Q27653715-6A887045-F400-427E-BE2B-436D6381C175

Q27653715-78ED8EBA-9D1A-450C-B823-996EF3C9BD1C

Q27653715-9B9F0BB0-58DF-4C2A-AF01-2CFC37D1D429

Q27653715-A2829550-1DF0-4BF6-B71A-C675E884C488

Q27653715-A888B501-E317-4FE6-A9A4-579A1BA1C595

Q27653715-B6E1103C-1883-47AB-86E0-1D38DDC66E92

P2860

Q27653715-0A6A8709-919A-42E7-8A74-FE4D9CD70A8F

Q27653715-0F73CBA4-A418-4B38-AB56-CFFCDDB84CE7

Q27653715-0FDE2E61-8E1B-498A-B753-2BB42E5C5DC2

Q27653715-1BF7F18E-63D6-46CA-AC21-108D437C3F6F

Q27653715-291F80FD-21EC-406B-B4AF-755A94B0C750

Q27653715-39B3947E-000D-426D-8C44-4889445DEC63

Q27653715-39EDEC87-5D4B-4322-BED6-21994DE099B3

Q27653715-3CB49354-3819-4951-A110-0CE450F6DB13

Q27653715-407E633F-EBBA-4D9D-A192-3CAB74AC9031

Q27653715-422F5FF6-C582-4639-8A1D-AEEBFB35EF76

P304

Q27653715-5FB9632A-1502-4A3E-AA0D-90528E0F5A4F

P31

Q27653715-BCAD32A1-78A7-4144-85A4-E4DCCA8535CB

P3181

Q27653715-37315340-E533-4959-B93D-AC5ADC6B8D0E

P356

Q27653715-2B0CDCF1-4A4E-442F-877F-BC3E9FC1F8AC

P407

Q27653715-272CE143-8DFC-4110-9DE0-6C3A3962068B

P433

Q27653715-AF99EFE2-5CA9-470B-BA50-C80FB6F825D3

P478

Q27653715-02168D98-FABF-4BF4-ADD7-BB3020E5C1EC

P577

Q27653715-079804D0-60CB-4DC3-9EA2-A88015EEBEEF

P698

Q27653715-5DF26EB1-22D4-4F83-BECA-E9CF743A8A02

P921

Q27653715-FD43320E-EB1A-44EB-8401-F4C513A7C8AE

P932

Q27653715-8A0FEE5E-D11F-4CBD-BE2E-660F4B449A09

P3181

P356

P1433

Journal of Biological Chemistry

P1476

Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION

@en

P2093

Adrian Moore

http://www.w3.org/2001/XMLSchema#string

Alistair J Henry

http://www.w3.org/2001/XMLSchema#string

Andrew Ventom

http://www.w3.org/2001/XMLSchema#string

Barbara Mulloy

http://www.w3.org/2001/XMLSchema#string

Chris Paszty

http://www.w3.org/2001/XMLSchema#string

Frederick W Muskett

http://www.w3.org/2001/XMLSchema#string

Jianhua Gong

http://www.w3.org/2001/XMLSchema#string

Kevin Greenslade

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Mariusz Muzylak

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding

Crystal structure of human platelet-derived growth factor BB

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

Structural basis for the inhibition of activin signalling by follistatin.

Structure of human follicle-stimulating hormone in complex with its receptor

The Protein Data Bank

N.m.r. and molecular-modelling studies of the solution conformation of heparin

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density

P304

10890-900

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3113115

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M807994200

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19208630

http://www.w3.org/2001/XMLSchema#string

P921

P932

2667775

http://www.w3.org/2001/XMLSchema#string